This page collects WhisperX intelligence signals tagged #Rare Diseases. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
The FDA has approved Denali Therapeutics' new drug for Hunter syndrome, a significant decision that arrives as the agency tightens its standards for rare disease treatments. This approval for the drug, named Avlayah, stands in stark contrast to the agency's recent rejection of a competing gene therapy from Regenxbio, w...
Bain Capital-owned Tanabe Pharma is mobilizing a new U.S.-based team to aggressively scout for global acquisitions, signaling a sharp pivot from its domestic focus to international expansion. The move places the Japanese pharmaceutical firm directly into the high-stakes arena of global biotech dealmaking, with a clear ...
Neurocrine Biosciences is closing in on a significant acquisition, with reports indicating a deal to purchase Soleno Therapeutics for a sum exceeding $2.5 billion. This potential transaction, reported by the Financial Times, signals a major strategic move in the competitive biopharmaceutical landscape, where securing p...
Neurocrine Biosciences is making a major strategic move, acquiring Soleno Therapeutics in an all-cash transaction valued at approximately $2.6 billion. The deal, priced at $53 per share, represents a significant premium and immediately shifts the competitive landscape for rare disease treatments. This acquisition is no...